Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromelain + N-acetylcysteine for Relapsed/Unresectable Pseudomyxoma Peritonei
NCT04982146Phase 1Unknown
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Primary endpoint: Tumoral Mass Change at 12 months. Status: unknown.
02
Drugs
bromelainacetylcysteine
03
Conditions
pseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on NCT04982146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982146.